CardioDx is committed to developing clinically validated tests that empower clinicians to better tailor care to individual patients. Focused on coronary artery disease, cardiac arrhythmia, and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency. We fuse expertise in genomics, biostatistics, and cardiology to develop objective, reproducible tests. In 2010, the company was a winner of the Wall Street Journal’s prestigious Technology Innovation Awards and Corus® CAD was named one of Time Magazine’s Top Ten Medical Breakthroughs.
CEO: David Levinson